Article
Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion
Strong Bullish
100.0
−100 Bearish
0
+100 Bullish
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
CNBC Top Stories
Published
Jun 9, 2026 · 10:13 am
Article ID
y07qb1y
Original URL
Open source
Sentiment Signal
Strong Bullish
100.0
−100Neutral+100
More Like This